Short Interest in Crescent Capital BDC, Inc. (NASDAQ:CCAP) Increases By 32.9%

Crescent Capital BDC, Inc. (NASDAQ:CCAP) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 131,700 shares, a growth of 32.9% from the March 15th total of 99,100 shares. Based on an average daily trading volume, of 94,900 shares, the days-to-cover ratio is presently 1.4 days.

Crescent Capital BDC Stock Down 0.9 %

CCAP stock opened at $16.96 on Monday. The company has a market cap of $628.54 million, a price-to-earnings ratio of 7.41 and a beta of 0.83. The company has a debt-to-equity ratio of 1.14, a current ratio of 0.98 and a quick ratio of 0.98. Crescent Capital BDC has a 12 month low of $13.11 and a 12 month high of $18.00. The company has a fifty day moving average price of $16.87 and a 200 day moving average price of $16.76.

Crescent Capital BDC (NASDAQ:CCAP) last announced its quarterly earnings data on Wednesday, February 21st. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $50.00 million during the quarter, compared to the consensus estimate of $47.99 million. Crescent Capital BDC had a net margin of 45.54% and a return on equity of 11.32%. Sell-side analysts expect that Crescent Capital BDC will post 2.26 earnings per share for the current year.

Crescent Capital BDC Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 29th will be given a dividend of $0.41 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.64 dividend on an annualized basis and a yield of 9.67%. Crescent Capital BDC’s payout ratio is currently 71.62%.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Oppenheimer upped their price target on shares of Crescent Capital BDC from $18.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, February 23rd. Wells Fargo & Company upped their price target on shares of Crescent Capital BDC from $16.00 to $16.50 and gave the company an “equal weight” rating in a research report on Monday, January 29th.

Hedge Funds Weigh In On Crescent Capital BDC

A number of large investors have recently bought and sold shares of CCAP. JPMorgan Chase & Co. purchased a new position in Crescent Capital BDC during the 1st quarter worth $185,000. Raymond James & Associates grew its stake in shares of Crescent Capital BDC by 96.3% during the 1st quarter. Raymond James & Associates now owns 89,250 shares of the company’s stock worth $1,589,000 after purchasing an additional 43,779 shares during the period. Ares Management LLC grew its stake in shares of Crescent Capital BDC by 54.0% during the 1st quarter. Ares Management LLC now owns 657,838 shares of the company’s stock worth $11,710,000 after purchasing an additional 230,593 shares during the period. UBS Group AG grew its stake in shares of Crescent Capital BDC by 48.2% during the 1st quarter. UBS Group AG now owns 6,645 shares of the company’s stock worth $118,000 after purchasing an additional 2,160 shares during the period. Finally, Captrust Financial Advisors grew its stake in shares of Crescent Capital BDC by 797.8% during the 1st quarter. Captrust Financial Advisors now owns 62,726 shares of the company’s stock worth $1,117,000 after purchasing an additional 55,739 shares during the period. Hedge funds and other institutional investors own 49.46% of the company’s stock.

About Crescent Capital BDC

Crescent Capital BDC, Inc is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.